Production of recombinant DT(ct)GMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies

Protein Expression and Purification

Volumn 13, Issue 2, 1998, Pages 210-221

  Williams, Mark D ^a   Rostovtsev, Alexander ^b   Narla, Rama Krishna ^b   Uckun, Fatih M ^b  

^a Alexander and Parker Corporation   (United States)

^b Department of Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; COLUMN CHROMATOGRAPHY; ESCHERICHIA COLI; EXPRESSION VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN EXPRESSION; TOXIN;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; INSECTA; UNIDENTIFIED BACULOVIRUS;

DIPHTHERIA TOXIN; DTCTGMCSF PROTEIN, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOTOXIN;

ACUTE DISEASE; ANIMAL; APOPTOSIS; ARMYWORM; ARTICLE; BACULOVIRUS; BIOASSAY; BIOSYNTHESIS; CELL STRAIN HL 60; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MYELOID LEUKEMIA; TOXICITY TESTING;

ACUTE DISEASE; ANIMALS; APOPTOSIS; BACULOVIRIDAE; BIOLOGICAL ASSAY; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOID; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS; SPODOPTERA; TOXICITY TESTS;

EID: 0032105476     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.1998.0900     Document Type: Article

References (48)

1. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J. Clin. 47:1997;5-27.
2. Schiffer C. A. Acute myeloid leukemia in adults. Cancer Med. 2:1993;2617-2649.
3. Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., Pastan I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol. 75:1990;340-345.
4. Pirker R., Wallner J., Geissler K., Linkesh W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. (Bethesda). 83:1991;708-712.
5. Musto P., Melillo L., Lombardi G., Matera R., di Giorgio G., Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol. 77:1991;50-53.
6. Arceci R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 81:1993;2215-2222.
7. Chan H. S., DeBoer G., Thorner P. S., Haddad G., Gallie B. L., Ling V. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol. Oncol. Clin. North Am. 8:1994;383-410.
8. Perentesis J. P., Waddick K. G., Bendel A. E., Shao Y., Warman B. E., Chandan- Langlie M., Uckun F. M. Induction of apoptosis in multidrug resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony stimulating factor receptor. Clin. Cancer Res. 3. 1997;347-355.
9. Bendel A. E., Shao Y., Davies S. M., Warman B., Yang C. H., Waddick K. G., Uckun F. M., Perentesis J. P. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leuk. & Lymphoma. 25:1997;257-270.
10. Perentesis J. P., Bendel A. E., Shao Y., Warman B., Davies S. M., Yang C. H., Chandan-Langlie M., Waddick K. G., Uckun F. M. Granulocyte- macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. Leuk. & Lymphoma. 25:1997;247-256.
11. Perentesis J. P., Gunther R., Waurzyniak B., Yanishevski Y., Myers D. E., Ek O., Messinger Y., Shao Y., Chelstrom L. M., Schneider E., Evans W. E., Uckun F. M. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony stimulating factor receptor. Clin. Cancer Res. 3:1997;2217-2227.
12. Chiou C. J., Wu M. C. Expression of human granulocyte-macrophage colony-stimulating factor gene in insect cells by a baculovirus vector. FEBS Lett. 259:1990;249-253.
13. Au L. C., Liu T. J., Shen H. D., Choo K. B., Wang S. Y. Secretory production of bioactive recombinant human granulocyte- macrophage colony-stimulating factor by a baculovirus expression system. J. Biotechnol. 51:1996;107-113.
14. O'Reilly D. R., Miller L. K., Luckow V. A. Baculovirus Expression Vectors: A Laboratory Manual. 1992;Freeman Press, New York.
15. Jones I., Morikawa Y. Baculovirus vectors for expression in insect cells. Curr. Opin. Biotechnol. 7:1996;512-516.
16. Griffiths C. M., Page M. J. Production of heterologous proteins using the baculovirus/insect expression system. Methods Mol. Biol. 75:1997;427-440.
17. Possee R. D. Baculoviruses as expression vectors. Curr. Opin. Biotechnol. 8:1997;569-572.
18. Vaughn J. L., Goodwin R. H., Tompkins G. J., McCawley P. The establishment of two cell lines from the insectSpodoptera frugiperda. In Vitro. 13:1977;213-217.
19. Williams M. D., Fieno A. M., Grant R. A., Sherman D. H. Expression and analysis of a bacterial poly(hydroxyalkanoate) synthase in insect cells using a baculovirus system. Protein Expr. Purif. 7:1996;203-211.
20. Collins S. J. The HL-60 promyelocytic leukemia cell line: Proliferation, differentiation, and cellular oncogene expression. Blood. 70:1987;1233-1244.
21. Langridge J., Langridge P., Bergquist P. L. Extraction of nucleic acids from agarose gels. Anal. Biochem. 103:1980;264-271.
22. Luckow V. A., Lee S. C., Barry G. F., Olins P. O. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated inEscherichia coli. J. Virol. 67:1993;4566-4579.
23. Kool M., Voncken J. W., van Lier F. L., Tramper J., Vlak J. M. Detection and analysis of Autographa californica nuclear polyhedrosis virus mutants with defective interfering properties. Virology. 183:1991;739-746.
24. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
25. Uckun F. M., Evans W. E., Forsyth C. J., Waddick K. G., Ahlgren L. T., Chelstrom L. M., Burkhardt A., Bolen J., Myers D. E. Biotherapy of B- cell precursor leukemia by targeting genistein to CD19- associated tyrosine kinases. Science. 267:1995;886-891.
26. Myers D. E., Jun X., Waddick K. G., Forsyth C., Chelstrom L. M., Gunther R. L., Tumer N. E., Bolen J., Uckun F. M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Proc. Natl. Acad. Sci. USA. 92:1995;9575-9579.
27. Green L. M., Reade J. L., Ware C. F. Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines. J. Immunol. Methods. 70:1984;257-268.
28. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods. 95:1986;99-105.
29. McCarthy N. J., Evan G. I. Methods for detecting and quantifying apoptosis. Curr. Top. Dev. Biol. 36:1998;259-278.
30. Uckun F. M., Tuel-Ahlgren L., Song C. W., Waddick K., Myers D. E., Kirihara J., Ledbetter J. A., Schieven G. L. Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. Proc. Natl. Acad. Sci. USA. 89:1992;9005-9009.
31. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
32. Fraser A., Evan G. A license to kill. Cell. 85:1996;781-784.
33. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
34. Murphy J. R., Bishai W., Borowski M., Miyanohara A., Boyd J., Nagle S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. USA. 83:1986;8258-8262.
35. Williams D. P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F., Strom T. B., Murphy J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1:1987;493-498.
36. Lakkis F., Steele A., Pacheco-Silva A., Rubin-Kelley V., Strom T. B., Murphy J. R. Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur. J. Immunol. 21:1991;2253-2258.
37. Jean L. F., Murphy J. R. Diphtheria toxin receptor-binding domain substitution with interleukin 6: Genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng. 4:1991;989-994.
38. Shaw J. P., Akiyoshi D. E., Arrigo D. A., Rhoad A. E., Sullivan B., Thomas J., Genbauffe F. S., Bacha P., Nichols J. C. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. 266:1991;21118-21124.
39. Meneghetti C. M., LeMaistre C. F. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486- IL-2). Targeted Diagn. Ther. 7:1992;395-401.
40. LeMaistre C. F., Meneghetti C., Rosenblum M., Reuben J., Parker K., Shaw J., Deisseroth A., Woodworth T., Parkinson D. R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 79:1992;2547-2554.
41. LeMaistre C. F., Craig F. E., Meneghetti C., McMullin B., Parker K., Reuben J., Boldt D. H., Rosenblum M., Woodworth T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res. 53:1993;3930-3934.
42. LeMaistre C. F., Saleh M. N., Kuzel T. M., Foss F., Platanias L. C., Schwartz G., Ratain M., Rook A., Freytes C. O., Craig F., Reuben J., Nichols J. C. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2. Blood. 91:1998;399-405.
43. Rivas C. I., Carlos Vera J., Delgado-Lopez F., Heaney M. L., Guaiquil V. H., Zhang R. H., Scher H. I., Concha I. I., Nualart F., Cordon-Cardo C., Golde D. W. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood. 91:1998;1037-1043.
44. Frankel A., Tagge E., Chandler J., Burbage C., Hancock G., Vesely J., Willingham M. IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Bioconjug. Chem. 6:1995;666-672.
45. Frankel A. E., Burbage C., Fu T., Tagge E., Chandler J., Willingham M. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Protein Eng. 9:1996;913-919.
46. Volkman L. E. Baculovirus bounty. Science. 269:1995;1834.
47. Kretzschmar T., Aoustin L., Zingel O., Marangi M., Vonach B., Towbin H., Geiser M. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J. Immunol. Methods. 195:1996;93-101.
48. Brocks B., Rode H. J., Klein M., Gerlach E., Dubel S., Little M., Pfizenmaier K., Moosmayer D. A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells. Immunotechnology. 3:1997;173-184.